Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
These trade-offs can cause headaches for even the most seasoned professionals, which is why we started StockStory - to help you find high-quality companies that can grow their earnings no matter what. That said, here are three large-cap stocks whose competitive advantages create flywheel effects.
Boeing (BA)
Market cap: $136.8 billion
One of the companies that forms a duopoly in the commercial aircraft market, Boeing (NYSE: BA) develops, manufactures, and services commercial airplanes, defense products, and space systems.
Why Does BA Catch Our Eye?
- Unit sales averaged 51.8% growth over the past two years and imply healthy demand for its products
- Earnings per share have massively outperformed its peers over the last two years, increasing by 60.5% annually
- Improving returns on capital suggest its past investments are beginning to deliver value
Boeing’s stock price of $170.95 implies a valuation ratio of 209.5x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
Trane Technologies (TT)
Market cap: $94.85 billion
With low-pressure heating systems as its first product, Trane (NYSE: TT) designs, manufactures, and sells HVAC and refrigeration systems, the former to commercial and residential building customers and the latter to commercial truck manufacturers.
Why Is TT a Top Pick?
- Annual revenue growth of 11.1% over the past five years was outstanding, reflecting market share gains this cycle
- Share repurchases have amplified shareholder returns as its annual earnings per share growth of 20.5% exceeded its revenue gains over the last five years
- Free cash flow margin grew by 10.6 percentage points over the last five years, giving the company more chips to play with
Trane Technologies is trading at $434.31 per share, or 26.1x forward P/E. Is now a good time to buy? See for yourself in our full research report, it’s free.
Vertex Pharmaceuticals (VRTX)
Market cap: $136.9 billion
Founded in 1989 with a mission to create medicines that treat the underlying causes of disease rather than just symptoms, Vertex Pharmaceuticals (NASDAQ: VRTX) develops and markets transformative medicines for serious diseases, with a focus on cystic fibrosis, sickle cell disease, and pain management.
Why Are We Fans of VRTX?
- Offerings and unique value proposition resonate with customers, as seen in its above-market 13.5% annual sales growth over the last five years
- Adjusted operating profits and efficiency rose over the last two years as it benefited from some fixed cost leverage
- ROIC punches in at 29.5%, illustrating management’s expertise in identifying profitable investments
At $552.80 per share, Vertex Pharmaceuticals trades at 27.5x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
Stocks we like even more
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
